HDAC6 and colorectal carcinoma: Here we showed that the combination of 5-FU with the HDAC6 inhibitor Tubastatin A, designed to target both the more committed CRC cells (by 5-FU) and the small but chemoresistant CSC fraction (by Tubastatin A), dramatically inhibited tumor growth in vivo with no significant in vivo toxicity.